Supernus Pharmaceuticals Inc (SUPN)

Debt-to-assets ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	—	—	—	—	—	0	0	400,382	379,252	374,788	370,383	366,038	361,751	357,521	353,349	349,232	345,170	341,163	337,210	333,310
Total assets	US$ in thousands	1	1,285,160	1,293,100	1,791,810	1,702,510	1,693,130	1,694,970	1,639,520	1,689,150	1,555,040	1,573,060	1,507,440	1,504,100	1,510,020	1,491,020	1,189,870	1,160,280	1,106,910	1,063,680	1,025,450
Debt-to-assets ratio		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.24	0.22	0.24	0.24	0.24	0.24	0.24	0.24	0.29	0.30	0.31	0.32	0.33

December 31, 2023 calculation

Debt-to-assets ratio = Long-term debt ÷ Total assets
= $—K ÷ $1K
= 0.00

The debt-to-assets ratio for Supernus Pharmaceuticals Inc has shown a consistent downward trend in recent quarters. In Q1 2023, the ratio increased to 0.27, indicating that 27% of the company's assets were funded by debt. This was a significant increase compared to the previous three quarters where the ratio stood at 0.24, suggesting that only 24% of assets were financed by debt.

However, it is worth noting that in the most recent quarter, Q4 2023, the debt-to-assets ratio dropped to 0.00, implying that the company had no debt relative to its total assets. This could indicate that Supernus Pharmaceuticals Inc has either paid off its debt or significantly decreased its borrowing levels.

Overall, the decreasing trend in the debt-to-assets ratio showcases an improving financial position for the company, as lower debt levels relative to assets can signify lower financial risk and greater financial stability. Investors and stakeholders may view this positively as it indicates a stronger balance sheet and a more conservative approach to debt management.